Entheos Labs
Entheos Labs is a Boston-based psychedelic medicines company founded in 2022 by Dr. Jerry Rosenbaum and Tristan Edwards, dedicated to discovering, developing, and deploying novel psychedelic medicines for unmet medical needs. The company is creating a pipeline of new chemical entities derived from overlooked natural psychedelic materials, with its lead candidate ET-01 targeting mood, anxiety, trauma, and substance use disorders.
Development Programmes
1ET-01 (Synthetic Neuroplastogen)
ET-01 is a synthetic neuroplastogen derived from botanically sourced psychedelic compounds. Potent 5-HT2A receptor agonist designed to promote rapid structural neuroplasticity (dendritic spine growth, synaptogenesis) without requiring a full psychedelic experience. Discovered through Entheos's proprietary iPSC-based high-throughput screening platform that measures neuroplasticity directly in human neurons. The platform screens unscheduled psychedelic-adjacent plant-derived compounds — finding the "Goldilocks" zone of neuroplastic efficacy without hallucinatory or scheduling liabilities. Co-founder Jerry Rosenbaum (Harvard/MGH psychiatry chair emeritus) brings deep clinical trial design expertise. CSO Darrick Balu leads preclinical characterisation.
Programme Tracker
Major Depressive Disorder (MDD)
iPSC-based high-throughput neuroplasticity screening underway. ET-01 identified as lead from botanical compound library. Preclinical characterisation in progress — no IND filed, no ClinicalTrials.gov entries. Company is entirely in discovery/preclinical stage. $3.58M seed capital secured Sep 2024, SEC Form D filed Oct 2024 for up to $10M raise. Team building with world-class SAB: Robin Carhart-Harris, Adam Gazzaley, Sarah O'Connor.
Milestones
Company milestone
CompletedActual: Jan 1, 2024
Entheos Labs founded by Jerry Rosenbaum (Harvard/MGH psychiatry chair emeritus) and A. Tristan Edwards (CEO). Focus on discovering non-psychedelic neuroplastogens from botanical sources using iPSC-based screening. Stephen Haggarty (MGH) serves as Chief Science Advisor.
Why it matters: Rosenbaum brings decades of Harvard psychiatry leadership and clinical trial expertise. Haggarty's MGH lab has pioneered iPSC-based psychiatric drug screening. Positions Entheos with elite academic credentials in a crowded neuroplastogen space.
Funding milestone
CompletedActual: Sep 17, 2024
$3.58M seed round closed. Investors: Lionheart Ventures, Satori Neuro, Conscience Capital, Possible Ventures, and additional angels. SEC Form D filed Oct 2024 indicating up to $10M total raise.
Why it matters: Seed funding enables iPSC screening platform buildout and preclinical characterisation of lead compounds. Investor base spans psychedelic-focused VCs (Satori Neuro, Conscience Capital) and broader biotech funds (Lionheart, Possible Ventures).
Company milestone
CompletedActual: Dec 1, 2024
Scientific Advisory Board assembled: Robin Carhart-Harris (UCSF, pioneered psilocybin neuroimaging), Adam Gazzaley (UCSF Neuroscape, digital therapeutics), Sarah O'Connor (Max Planck Institute, plant alkaloid biosynthesis). CSO: Darrick Balu (Harvard-trained neuroscientist).
Why it matters: Elite SAB combines psychedelic neuroscience leadership (Carhart-Harris), translational technology expertise (Gazzaley), and plant chemistry authority (O'Connor). Signals serious scientific credibility despite early stage.
Recorded Events
Dec 1, 2024: Company milestone
Sep 17, 2024: Funding milestone
Jan 1, 2024: Company milestone
Evidence Links
company-website - Entheos Labs - Verified
industry-media - Psychedelic Alpha - plausible
Quick Facts
- Type
- Private Biotech
- Founded
- 2022
- Lead Stage
- Discovery
- Website
- Visit